Bridgeway Capital Management, LLC Leap Therapeutics, Inc. Transaction History

Bridgeway Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.96 - $1.91 $125,952 - $250,592	131,200 Added 78.52%	298,301 $343,000
Q4 2021 Feb 14, 2022	SELL	$2.08 - $3.65 $166,400 - $292,000	-80,000 Reduced 32.38%	167,101 $541,000
Q3 2021 Nov 15, 2021	SELL	$1.35 - $4.01 $170,775 - $507,265	-126,500 Reduced 33.86%	247,101 $991,000
Q2 2021 Aug 16, 2021	SELL	$1.48 - $1.92 $95,460 - $123,840	-64,500 Reduced 14.72%	373,601 $613,000
Q1 2021 May 17, 2021	BUY	$1.82 - $3.01 $347,803 - $575,214	191,101 Added 77.37%	438,101 $832,000
Q4 2020 Feb 16, 2021	BUY	$1.49 - $2.37 $47,680 - $75,840	32,000 Added 14.88%	247,000 $556,000
Q3 2020 Nov 16, 2020	BUY	$1.68 - $2.17 $137,760 - $177,940	82,000 Added 61.65%	215,000 $426,000
Q2 2020 Aug 14, 2020	BUY	$1.39 - $2.84 $184,870 - $377,720	133,000 New	133,000 $278,000
Q4 2019 Feb 14, 2020	SELL	$0.63 - $1.37 $22,869 - $49,731	-36,300 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.15 - $7.14 $186,945 - $259,182	36,300	36,300 $211,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $254M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.